Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22750792 | 0.89 | KDM4E (0.40) | ALDH1A1TSHRKDM4EUSP2LMNA | |
| SCHEMBL19197241 | 0.89 | SMYD2 (0.38) | ALDH1A1TSHRKDM4EUSP2LMNA | |
| SCHEMBL23227787 | 0.80 | CA2 (0.36) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL23121114 | 0.80 | L3MBTL1 (0.43) | ALDH1A1TSHRMMP9SMN1; SMN2CYP3A4 | |
| SCHEMBL7868268 | 0.79 | CYP3A4 (0.34) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL23120633 | 0.79 | SMYD2 (0.35) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL31738087 | 0.79 | SMYD2 (0.35) | ALDH1A1SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL23120948 | 0.79 | KCNH3 (0.37) | ALDH1A1TSHRKDM4ESMYD2SMN1; SMN2 | |
| SCHEMBL21987715 | 0.79 | SMYD2 (0.35) | ALDH1A1TSHRSMYD2SMN1; SMN2CYP3A4 | |
| SCHEMBL31645339 | 0.79 | SMYD2 (0.36) | ALDH1A1TSHRKDM4EUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-08 | — | — | US | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| WO-2021053495-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387602-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | JMJD7, MDM2, IDE | ALDH1A1 2189/4885TSHR 2854/4885KDM4E 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.